Reportedly, Pantarhei now has secured backing from international private equity investors.
Reuters quoted Pantarhei Bioscience director (and former Organon executive) Herjan Coeling Bennink as telling the Dutch Financieele Dagblad that the company is thinking of making the proposal thanks to the backing from international private equity investors.
Merck had postponed the closure of Organon’s R&D activities in Holland while it negotiated on potential alternatives including a sale, the initial deadline of which was 31 December 2010 which was later pushed back to 15 February.